Salix's Pharmaceuticals (SLXP) Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission From Ulcerative Colitis

June 2, 2009 9:08 AM EDT

Data was announced today that demonstrated Salix Pharmaceuticals' (NASDAQ: SLXP) APRISO (mesalamine) 0.375g extended-release capsules had a favorable safety profile in patients in remission from ulcerative colitis (UC) for up to 24 months. APRISO is approved for use up to six months. The majority of treatment-emergent adverse events were mild or moderate in intensity, and were similar to what was seen during the 6-month phase 3 trials. The study, which is the first to examine the long-term safety profile of APRISO, was presented at the Digestive Disease Week (DDW) annual meeting in Chicago, Illinois.

"It is important to provide UC patients with a new treatment option that can be safely used over the long-term," said Dr. Glenn L. Gordon, Medical Director and President of the Center for Digestive and Liver Diseases, Inc. in Mexico, Missouri. "The favorable long-term safety profile of APRISO, combined with once-daily dosing, may support its use as first-line therapy for long-term* maintenance of UC remission."

Related Categories

Corporate News
FDA
Hot List

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?